Integrated Filing- Financial

**Revenue Performance:** Mangalam Drugs and Organics Ltd. has announced a board meeting on August 7, 2025, where it approved the financial results for the quarter ended June 30, 2025. The company reported a significant drop in total revenue from operations, which stood at Rs 57.21 Cr for Q1 FY26, down sharply by 25.21% year-on-year compared to Rs 76.49 Cr in Q1 FY25. The company operates in a single segment: Manufacturing of Bulk Drugs. **Profitability and EPS:** This steep decline in revenue led to a net loss of Rs 13.80 Cr for the quarter, a significant reversal from a net profit of Rs 2.68 Cr in the same quarter last year.

Basic Earnings Per Share (EPS) turned negative at Rs (8.72) from Rs 1.70 previously. **Operational Costs:** While Cost of Materials Consumed decreased to Rs 23.34 Cr from Rs 40.53 Cr, and Other Expenses also saw a reduction, these cost controls were insufficient to offset the substantial revenue fall.

Finance costs increased marginally, further impacting the bottom line. **Management Commentary / Strategic Outlook:** A key update is the ongoing Scheme of Merger by Absorption involving Mangalam Laboratories Pvt Ltd and Shri JB Pharma Pvt Ltd with Mangalam Drugs and Organics.

A meeting for creditors and shareholders is set for August 12, 2025, to discuss this corporate action. **Final Takeaway:** The latest results indicate weak momentum, primarily due to a substantial fall in sales.

Investors should monitor the progress of the merger as a potential future business development that could impact the company's structure and operations.